SanguiBioTech GmbH: Preclinical Trials Demonstrate: Sangui Hemoglobin Preparation Improves Oxygen Supply Of Vital Organs
WITTEN, Germany--(BUSINESS WIRE)--A possible success in treating septic shock has now been attained by the research team embracing SanguiBioTech GmbH, the Excellence Cluster Cardio Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH. Preclinical trials at Giessen University underpin that a hemoglobin based product developed by SanguiBioTech is apt to improve the oxygen supply of vital organs. It is now being supposed that Sangui's hemoglobin-based artificial oxygen carriers may interrupt the self-perpetuating mechanism of septic shock, that has so far been highly resistant to treatment, and may thus ultimately reduce the high mortality rates.
A septic shock is the life threatening final phase of a sepsis. The blood circulation, else exactly tuned to meet the needs of the body, begins to severely malfunction which results in deficient oxygen supply of the body tissue. This hypoxia induces a progressional intoxication of the body with bacteria and bacteria debris. Modern medical science has not yet identified suitable therapies to effectively fight this self-perpetuating mechanism of septicemia, which, therefore, results in mortality rates of 50 to 60 percent.
Preclinical trials in Giessen now demonstrate that an oxygen-carrying hemoglobin liquid in the abdomen did significantly improve the oxygen supply to the intestines. This is likely to be a decisive new therapeutic approach to disrupting this lethal loop. The preclinical trials are being continued as planned, extending the scope to additional indications such as ARDS (acute respiratory distress syndrome) and further hemoglobin preparations as developed by SanguiBioTech.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
ECCPS is an organization set up jointly by the universities of Frankfurt and Giessen together with the Max Planck Institute for Heart and Lung Research in Bad Nauheim. It ranks among the world's leading organizations of this type. This unique centre for translational medicine combines innovative medical research in the field of heart and lung diseases with their practical advancements based on preclinical and clinical studies. Its aim is to work together with industry on developing innovative drugs and substances.
TransMIT Gesellschaft für Technologietransfer mbH (www.transmit.de) being the unit in charge of technology transfer at Justus-Liebig University in Giessen is involved in carrying out this project.
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Sangui Biotech
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
Help employers find you! Check out all the jobs and post your resume.
A septic shock is the life threatening final phase of a sepsis. The blood circulation, else exactly tuned to meet the needs of the body, begins to severely malfunction which results in deficient oxygen supply of the body tissue. This hypoxia induces a progressional intoxication of the body with bacteria and bacteria debris. Modern medical science has not yet identified suitable therapies to effectively fight this self-perpetuating mechanism of septicemia, which, therefore, results in mortality rates of 50 to 60 percent.
Preclinical trials in Giessen now demonstrate that an oxygen-carrying hemoglobin liquid in the abdomen did significantly improve the oxygen supply to the intestines. This is likely to be a decisive new therapeutic approach to disrupting this lethal loop. The preclinical trials are being continued as planned, extending the scope to additional indications such as ARDS (acute respiratory distress syndrome) and further hemoglobin preparations as developed by SanguiBioTech.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
ECCPS is an organization set up jointly by the universities of Frankfurt and Giessen together with the Max Planck Institute for Heart and Lung Research in Bad Nauheim. It ranks among the world's leading organizations of this type. This unique centre for translational medicine combines innovative medical research in the field of heart and lung diseases with their practical advancements based on preclinical and clinical studies. Its aim is to work together with industry on developing innovative drugs and substances.
TransMIT Gesellschaft für Technologietransfer mbH (www.transmit.de) being the unit in charge of technology transfer at Justus-Liebig University in Giessen is involved in carrying out this project.
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Sangui Biotech
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
Help employers find you! Check out all the jobs and post your resume.